Detalles de la búsqueda
1.
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective.
Int J Mol Sci
; 24(15)2023 Jul 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37569269
2.
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells.
Int J Mol Sci
; 24(22)2023 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38003483
3.
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC).
Int J Mol Sci
; 24(6)2023 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36982938
4.
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients.
Anticancer Drugs
; 33(1): e628-e634, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34407044
5.
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic.
Eur J Clin Pharmacol
; 78(11): 1791-1800, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36102931
6.
Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study.
BMC Public Health
; 22(1): 2137, 2022 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36411406
7.
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9).
Breast Cancer Res Treat
; 190(1): 103-109, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34453206
8.
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.
BMC Cancer
; 21(1): 260, 2021 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33691674
9.
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale.
Eur J Cancer Care (Engl)
; 30(1): e13334, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33015898
10.
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
BMC Cancer
; 20(1): 232, 2020 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32188417
11.
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.
Breast Cancer Res Treat
; 176(3): 483-494, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31065872
12.
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Oncologist
; 22(6): 648-654, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28432226
13.
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer.
Biomedicines
; 12(2)2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38397874
14.
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer.
JNCI Cancer Spectr
; 8(1)2024 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38113421
15.
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project.
Front Oncol
; 13: 1247270, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37954071
16.
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.
Cancers (Basel)
; 16(1)2023 Dec 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38201545
17.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Front Oncol
; 13: 1152123, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37260975
18.
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows.
J Clin Med
; 11(16)2022 Aug 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36012949
19.
Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything.
Cancers (Basel)
; 14(15)2022 Jul 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35954393
20.
How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story.
Life (Basel)
; 12(3)2022 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35330128